US IPOs and Secondary Offerings, IPO Boutique

IPO Boutique

For more than 20 years, we have been providing research, analysis, commentary and ratings on US Equity Capital Markets to institutional investors (US IPOs and Secondary Offerings). Our vast network of contacts across the Equity Capital Markets and attention-to-detail sets us apart from our competitors.

Since 2012, we have achieved a successful hit rating on 89% of Buy-rated IPOs. The collective “Buy” ratings averaged a first trade of 16.3% above issue.Our Neutral Rated Deals averaged just 2% above the issue price at first trade.

Our written research includes pre-IPO notes before the deal is launched, follow-up analysis once the deal is live and post-listing trading analysis as well.

In addition, we provide a high-touch premium desk access which includes analyst access, as well as real time insights on US IPOs as well as secondary offerings.

US IPOs and Secondary Offerings

LB Pharmaceuticals Inc. (LBRX): Schizophrenia Biotech Sets Terms, Readies for Same-Week Debut

LB Pharmaceuticals Inc. (LBRX): Clubby Deal Expected in Thursday's Schizophrenia Biotech IPO

LB Pharmaceuticals Inc. (LBRX): Strong Open, Schizophrenia Biotech Finds Early Momentum

IPOs and Secondary Offerings

Equity Capital Markets

LB Pharmaceuticals / Equity Capital Markets

<ul>
<li>Their product candidate, LB-102, is a Phase 3-ready oral, small molecule for the treatment of acute schizophrenia, defined as a sudden and severe episode of psychotic symptoms.</li>
<li>The largest holder is Deep Track Biotechnology Master Fund, Ltd., controlling 16.7 million shares, or 19.6% of the company.</li>
<li>There has not been a biotech IPO since Aardvark Therapeutics in mid February. This biotech may be more well-received given that its lead product candidate is in Phase III.</li>
</ul>


Their product candidate, LB-102, is a Phase 3-ready oral, small molecule for the treatment of acute schizophrenia, defined as a sudden and severe episode of psychotic symptoms.
The largest holder is Deep Track Biotechnology Master Fund, Ltd., controlling 16.7 million shares, or 19.6% of the company.
There has not been a biotech IPO since Aardvark Therapeutics in mid February. This biotech may be more well-received given that its lead product candidate is in Phase III.


LB Pharmaceuticals Inc. (LBRX): Peeking at the IPO Prospectus of Schizophrenia Product Candidate Bio